Skip to Main Content
Immune System, Phase III

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)

What is the purpose of this trial?

To evaluate the long-term safety and tolerability of seladelpar.

  • Trial with
    CymaBay Therapeutics, Inc.
  • Ages
    18 years - 75 years
  • Gender
    Both

Contact Information

For more information about this study, including how to volunteer, contact Suzie Christopher

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

  • Last Updated
    04/21/2023
  • Study HIC
    #2000030598